Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer
- 21 May 2004
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 203 (3) , 762-770
- https://doi.org/10.1002/path.1567
Abstract
Loss of heterozygosity, mutations or deletions of the RB1 gene usually result in loss of pRb expression, which has been regarded as an indicator of loss of pRb function in human tumours. It has previously been shown that in addition to loss of pRb expression, aberrantly high (pRb2+) pRb expression also indicates loss of pRb function in bladder tumours compared with moderate (normal, pRb1+) pRb expression. The aim of this study was to elucidate the mechanism by which pRb is functionally inactivated in bladder tumours expressing aberrantly high levels of pRb. Constitutive phosphorylation was therefore investigated as a mechanism of pRb inactivation in bladder tumours. Of 28 bladder tumours examined, western blotting demonstrated pRb hyperphosphorylation in 5/7 (71%) pRb2+ bladder tumours compared with only 4/11 (36%) pRb1+ tumours (p = 0.002). All cases with undetectable pRb showed moderate to high p16 expression and none showed cyclin D1 expression by immunohistochemistry. All pRb1+ tumours with underphosphorylated pRb showed p16 but not cyclin D1 expression. All pRb2+ tumours with hyperphosphorylated pRb showed loss of p16 expression and/or cyclin D1 overexpression. Thus, elevated pRb expression was associated with pRb hyperphosphorylation, which, in turn, was associated with loss of p16 expression and/or increased cyclin D1 expression. In order to analyse this association in vitro, T24 cells, which express high levels of pRb, were transfected with p16 cDNA. Transfection with p16 cDNA resulted in a marked decrease in pRb phosphorylation, decreased cell proliferation, and a change in expression of pRb from high to moderate phenotype as assessed by immunohistochemistry. This paper gives the biological basis for constitutive alteration of pRb function in human tumours in the presence of an intact, expressed pRb protein; the mechanism of pRb inactivation is through hyperphosphorylation, which results from loss of p16 expression and/or cyclin D1 overexpression. Immunohistochemical expression of pRb appears to be a reliable indicator of pRb function. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancerOncogene, 1999
- Inverse Association Between Cyclin D1 Overexpression and Retinoblastoma Gene Mutation in Thyroid CarcinomasEndocrine, 1998
- Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancersBritish Journal of Cancer, 1997
- Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomasNature Medicine, 1997
- Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemiaBlood, 1994
- Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progressionInternational Journal of Cancer, 1993
- Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder CancerJNCI Journal of the National Cancer Institute, 1992
- SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility geneCell, 1988